Steinhart Richard I's Form 4 filing
BioXcel Therapeutics, Inc. (BTAIQ) · filed May 22, 2026
- Accession no.
- 0001104659-26-065838
- Filed
- May 22, 2026
- Trade date
- May 4-20, 2026
- Filing delay
- 18 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $7.46K. It was filed 18 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Steinhart Richard ICIK 0001293789 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Common Stock | MOption exerciseAcquired | +17,500 | – | – | 33,145 | Direct | |
| May 20, 2026 | Common Stock | SSaleDisposed | −6,845 | $1.09 | −$7,461.05 | 26,300 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Common Stock | MOption exerciseDisposed | −17,500 | $0.00 | $0 | 52,500 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.